2033-44-5

Upstream product

• 95-20-5 2-methyl-1H-indole 
• 64-17-5 ethanol 
• 7553-56-2 iodine 

Downstream Products

• 1391983-94-0 3-phenyl-4-(4-methoxyphenyl)-1-(phenylsulfonyl)-β-carbonline 
• 1391983-95-1 3-phenyl-4-(2-methoxyphenyl)-1-(phenylsulfonyl)-β-carbonline 
• 1391983-96-2 3-phenyl-4-cyclopropyl-1-(phenylsulfonyl)-β-carbonline 
• 1391983-97-3 3-phenyl-4-(3-nitrophenyl)-1-(phenylsulfonyl)-β-carbonline 
• 1391983-98-4 3-phenyl-4-(3-formylphenyl)-1-(phenylsulfonyl)-β-carbonline 
• 1391983-99-5 3-phenyl-4-(4-fluorophenyl)-1-(phenylsulfonyl)-β-carbonline 
• 1410237-54-5 3-phenyl-4-(4-fluorophenyl)-1-(phenylsulfonyl)-β-carbonline 
• 1391984-01-2 3-phenyl-4-(2-bromophenyl)-1-(phenylsulfonyl)-β-carbonline 
• 1391983-79-1 C₂₄H₁₈N₂ 
• 1391983-80-4 C₂₄H₁₈N₂O 
• 1391983-81-5 C₂₄H₁₈N₂O 
• 1391983-82-6 C₂₀H₁₆N₂ 
• 1391983-83-7 C₂₃H₁₅N₃O₂ 
• 1391983-84-8 C₂₄H₁₆N₂O 

Relevant academic research and scientific papers

Halogenations of substituted 2-alkylquinoline with iodine and halide exchange with AgF2

Halogenations of substituted 2-alkylquinoline with iodine and halide exchange with AgF2 have been developed. These processes provide facile strategies to construct C-I/F bonds, and expand the methods of fluorination of 2-alkylquinolines. These transformations exhibit good tolerance of functional groups and generate the desired products in moderate to good yields.

A Versatile C–H Halogenation Strategy for Indole Derivatives under Electrochemical Catalyst- and Oxidant-Free Conditions

Halogenated indoles are essential structural motifs in bioactive natural products. Reported herein is an economical and scalable electrochemical protocol for regioselective 3C–H halogenation of indole derivatives. This strategy provides access to a host of 3-iodo-, 3-bromo-, 3-chloro-, and 3-thiocyanoindole derivatives under mild conditions using inexpensive (pseudo)halide salts as the sole reagent. The optimized conditions do not require any supplementary electrolyte salts.

Electrochemical sulfenylation of indoles with disulfides mediated by potassium iodide

A novel electrochemical system for sulfenylation of indoles with disulfides to generate 3-sulfenylindoles via C-S bond formation mediated by potassium iodide at a low potential was developed. Iodine was electrogenerated from iodide ions at a graphite anode and showed a high catalytic activity for the electrochemical sulfenylation reactions. A variety of aromatic, heteroaromatic and aliphatic disulfides could react with 2-methlyindole to synthesize the corresponding 3-sulfenylindoles in good to excellent yields. In addition, protected and unprotected indoles with various groups, especially electron-donating groups, also performed well in the sulfenylation reactions. The transformation, which proceeded through the redox of iodine and the generation of intermediate 3-iodoindole, provided an efficient and environmentally benign protocol for the synthesis of 3-sulfenylindoles under mild conditions.

INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase (e.g., CDK7), and therefore induce cellular apoptosis and/or inhibit transcription in the subject.

POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing' s sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7), cyclin-dependent kinase 12 (CDK12), or cyclin-dependent kinase 13 (CDK13)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

Synthesis and cytotoxic activity of 3-phenyl-4-substituted-β- carbolines

A new class of 3-phenyl-4-substituted-β-carbolines via iodine-mediated electrophilic cyclization as key step were synthesized and their inhibitory activity against three tumor cell lines was evaluated in vitro. It was found that some of the tested compoun

A simple iodination protocol via in situ generated ICl using NaI/FeCl 3

A novel iodination of silyl-enol ethers using hitherto unexplored NaI/FeCl3 system is reported. The procedure has been extended to the iodination of aromatic and hetero aromatic compounds.